Pharmacoeconomic evaluation of rifaximin combined with lactulose for the treatment of type C hepatic encephalopathy in China
OBJECTIVE To conduct the pharmacoeconomic evaluation of rifaximin combined with lactulose for the treat-ment of type C hepatic encephalopathy.METHODS A Markov model was constructed to simulate the long-term health out-comes and costs of rifaximin combined with lactulose versus lactulose for the treatment of type C hepatic encephalopathy based on the perspective of Chinese health system.Clinical efficacy was derived from published clinical randomize controlled trials,cost data from published literature,clinical experts research and publicly available databases,and utility values from published UK population studies.One-way sensitivity analysis and probabilistic sensitivity analysis(PSA)were used to verify the robustness of the results.RESULTS Base-case analysis results showed that compared with lactulose alone,rifaximin combined with lactulose increased health benefits by 1.67 QALYs and treatment costs by RMB 44 861.42 for patients with type C hepatic encephalopathy,with an incremental cost-effect ratio of RMB 26 832.28/QALY.When the per capita GDP in 2021(80 976 yuan)was used as the payment threshold,rifaximin combined with lactulose is a treatment scheme with economic advantage.One-way sensitivity analy-sis and probabilistic sensitivity analysis verified the robustness of the model and analysis results.CONCLUSION Rifaximin com-bined with lactulose is more cost-effective than lactulose alone for treating patients with type C hepatic encephalopathy.
rifaximinlactulosetype C hepatic encephalopathyMarkov modelcost-utility analysis
NETL
NSTL
万方数据
维普
